SAC3 domain containing 1 intervention in energy metabolism reprogramming assists in the progression of hepatocellular carcinoma

Figure 6 The inhibitor of β-Catenin, iCRT3, can attenuate the cellular phenotypes induced by SAC3 domain containing 1 overexpression. ^aP < 0.05,^cP < 0.001. A: The iCRT3 antagonizes the enhanced cell proliferation ability caused by SAC3 domain containing 1 overexpression, bar = 100 μm; B: The iCRT3 antagonizes the enhanced cell migration ability caused by SAC3 domain containing 1 overexpression, bar = 200 μm; C: Western blotting analysis of the effects of the β-Catenin antagonist iCRT3 on the expression of c-Myc, glucose transporter 1, hexokinase 2, pyruvate kinase M2 and lactate dehydrogenase A. SAC3D1: SAC3 domain containing 1; EdU: 5-ethynyl-2’-deoxyuridine; GLUT1: Glucose transporter 1; HK2: Hexokinase 2; PKM2: Pyruvate kinase M2; LDHA: Lactate dehydrogenase A.